… for some patients as maintenance therapy in combination with long-acting bronchodilators.3
… a smaller proportion of patients with severe (FEV 1 ≥30%–<50% predicted) or very severe …

… that a small percentage of COPD patients would benefit from single long acting bronchodilators,
named … < 50% predicted and ≥1 moderate/severe exacerbation in the previous year. …

… The criteria for inclusion were (1) a diagnosis of stable COPD; (2) age … patients with no
long-acting bronchodilators. While 96 (71.1%) patients were receiving the regimen for treatment …

… patients with severe COPD, guidelines recommend the use of an additional long-acting
bronchodilator with the LABA/ICS treatment… (1) characteristics resulting from the predictive model …

… either started or switched to a regimen containing a long-acting β 2 -… characteristics of the
overall group of patients who on entering DACCORD were receiving dual bronchodilation with …

… (GOLD) recommends classifying patients according to severity … treatment is based on one
or two long-acting bronchodilators, … 4 Predictive value of the different characteristics of patients …

… of patients with COPD can fail to achieve adequate control of symptoms or exacerbation risk
reduction while receiving only a long-acting bronchodilator, … strongest predictor of a patient's …

… with a single long-acting bronchodilator, combining a LAMA … FEV 1 per cent predicted ranged
from 37.2% to 57.4%. The … /LAMA combinations for stable COPD demonstrated that LABA/…

… 1 ) <80% of predicted in the presence of a post-bronchodilator FEV 1 to forced vital capacity
… long-acting bronchodilators with cardiovascular outcomes among patients with stable COPD…

… COPD treatment is based on long-acting bronchodilators with single agents or in combination,
depending on the patient's … in recent years on the predictive role of peripheral eosinophilia …